Glaukos Corporation (NYSE:GKOS – Get Free Report) COO Joseph Gilliam sold 44,917 shares of Glaukos stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $246.32, for a total transaction of $11,063,955.44. Following the sale, the chief operating officer directly owned 71,602 shares of the company’s stock, valued at $17,637,004.64. This represents a 38.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Glaukos Stock Performance
Shares of Glaukos stock traded down $0.69 on Monday, hitting $245.03. 848,336 shares of the company’s stock traded hands, compared to its average volume of 1,924,346. The firm’s 50-day moving average price is $185.95 and its two-hundred day moving average price is $147.70. Glaukos Corporation has a one year low of $87.32 and a one year high of $255.18. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.09 and a current ratio of 4.57.
Glaukos (NYSE:GKOS – Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.57. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The company had revenue of $211.03 million for the quarter, compared to the consensus estimate of $168.04 million. During the same quarter in the prior year, the business posted ($0.16) EPS. The firm’s quarterly revenue was up 58.0% on a year-over-year basis. Equities analysts anticipate that Glaukos Corporation will post 0.50 earnings per share for the current year.
Analysts Set New Price Targets
GKOS has been the subject of a number of recent analyst reports. Stifel Nicolaus upped their price objective on Glaukos from $190.00 to $225.00 and gave the company a “buy” rating in a report on Thursday, October 29th. UBS Group initiated coverage on Glaukos in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $150.00 target price on the stock. Mizuho set a $225.00 target price on Glaukos in a report on Thursday, October 29th. BTIG Research boosted their target price on Glaukos from $234.00 to $252.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Glaukos presently has an average rating of “Moderate Buy” and an average price target of $218.00.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Soleus Capital Management L.P. bought a new stake in shares of Glaukos during the third quarter worth $4,195,000. Cetera Investment Advisers raised its holdings in shares of Glaukos by 6.1% during the third quarter. Cetera Investment Advisers now owns 3,402 shares of the medical instruments supplier’s stock worth $559,000 after acquiring an additional 197 shares during the period. Entropy Technologies LP bought a new stake in Glaukos in the 3rd quarter valued at $402,000. Jump Financial LLC bought a new stake in Glaukos in the 3rd quarter valued at $2,014,000. Finally, Pathstone Holdings LLC lifted its position in Glaukos by 9.0% in the 3rd quarter. Pathstone Holdings LLC now owns 17,676 shares of the medical instruments supplier’s stock valued at $2,902,000 after acquiring an additional 1,462 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.
Glaukos Company Profile
Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.
Recommended Stories
- Five stocks we like better than Glaukos
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
